L1CAM mediates neuroendocrine phenotype acquisition in prostate cancer cells

Abstract

AbstractBackgroundA specific type of prostate cancer (PC) that exhibits neuroendocrine (NE) differentiation is known as NEPC. NEPC has little to no response to androgen deprivation therapy and is associated with the development of metastatic castration‐resistant PC (CRPC), which has an extremely poor prognosis. Our understanding of genetic drivers and activated pathways in NEPC is limited, which hinders precision medicine approaches. L1 cell adhesion molecule (L1CAM) is known to play an oncogenic role in metastatic cancers, including CRPC. However, the impact of L1CAM on NEPC progression remains elusive.MethodsL1CAM expression level was investigated using public gene expression databases of PC cohorts and patient‐derived xenograft models. L1CAM knockdown was performed in different PC cells to study in vitro cell functions. A subline of CRPC cell line CWR22Rv1 was established after long‐term exposure to abiraterone to induce NE differentiation. The androgen receptor‐negative cell line PC3 was cultured under the tumor sphere‐forming condition to enrich cancer stemness features. Several oxidative stress inducers were tested on PC cells to observe L1CAM‐mediated gene expression and cell death.ResultsL1CAM expression was remarkably high in NEPC compared to CRPC or adenocarcinoma tumors. L1CAM was also correlated with NE marker expressions and associated with the adenocarcinoma‐to‐NEPC progression in gene expression databases and CRPC cells with NE differentiation. L1CAM also promoted cancer stemness and NE phenotypes in PC3 cells under cancer stemness enrichment. L1CAM was also identified as a reactive oxygen species‐induced gene, by which L1CAM counteracted CRPC cell death triggered by ionizing radiation.ConclusionsOur results unveiled a new role of L1CAM in the acquisition of the NE phenotype in PC, contributing to the NE differentiation‐related therapeutic resistance of CRPC.